Proposal for a standardized PSA doubling-time calculation

Anticancer Research

Volumn 30, Issue 5, 2010, Pages 1633-1636

  Ponholzer, Anton ^a   Popper, Nikolaus ^b,c   Breitenecker, Felix ^c   Schmid, Hans Peter ^d   Albrecht, Walter ^e   Loidl, Wolfgang ^f   Madersbacher, Stephan ^a   Schramek, Paul ^g   Semjonow, Axel ^h   Rauchenwald, Michael ^a  

^a DANUBE HOSPITAL   (Austria)

^b Die Drahtwarenhandlung Simulation Services   (Austria)

^c Institute for Analysis and Scientific Computing   (Austria)

^d Kantonsspital St Gallen Klinik fur Urologie   (Switzerland)

^e KH Mistelbach ^*  (Austria)

^f Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

^g KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^h UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Kinetics; Prognosis; Prostate cancer; Tumor marker

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANALYTICAL ERROR; CALCULATION; CANCER GROWTH; CANCER SURVIVAL; CASE REPORT; CONFERENCE PAPER; HUMAN; INTERNET; MALE; MEASUREMENT; PRIORITY JOURNAL; PROSTATE CANCER; SIMULATION;

COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; HUMANS; KINETICS; LABORATORY TECHNIQUES AND PROCEDURES; LEAST-SQUARES ANALYSIS; MALE; MODELS, THEORETICAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954619595     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Maffezzini M, Bossi A and Collette L: Implications of PSA doubling time as indicator of failure after surgery or radiation therapy fpr prostate cancer. Eur Urol 51(3): 605-613, 2006.
2. Schmid HP, McNeal JE and Stamey TA: Observations on the doubling-time of prostate cancer. Cancer 71: 2031-2040, 1993.
3. Schmid HP, Morant R, Bernhard J and Maibach R for the Swiss Group for Clinical Cancer Research (SAKK): Prostate-specific antigen doubling-time as auxiliary end point in hormone-refractory prostate carcinoma. Eur Urol 43: 28-30, 2003.
4. Schmid HP, Prikler L, Sturgeon CM and Semjonow A: Diagnosis of prostate cancer - the clinical use of PSA. EAU Update series 1: 3-8, 2003.
5. Klotz L: Active surveillance with selective delayed intervention using PSA doubling-time for good risk prostate cancer. Eur Urol 47(1): 16-21, 2005. (Pubitemid 39575713)
6. D'Amico AV, Cote K, Loffredo M, Renshaw AA and Schultz D: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20: 4567-4573, 2002. (Pubitemid 35402960)
7. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD and Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597, 1999.
8. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ and Walsh PC: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433-439, 2005. (Pubitemid 41124175)
9. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC and Partin AW: Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling-time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25(13): 1765-1771, 2007.
10. Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJ and Schröder FH: Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling-times, and outcome. Eur Urol 51(5): 1244-1250, 2007.
11. Daskivich TJ, Regan MM and Oh WK: PSA doubling-time calculation: not as easy as 1, 2, 4. J Urol 176: 1927-1937, 2006.
12. Svatek RS, Shulman M, Choudhary PK and Benaim E: Critical analysis of PSA doubling-time calculation methodology. Cancer 106: 1047-53, 2006.
13. Sölétormos G, Semjonow A, Sibley PEC, Lamerz R, Petersen PH, Albrecht W, Bialk P, Gion M, Junker F, Schmid HP and Van Poppel H on behalf of the European Group on Tumor Markers: Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 51: 1342-1351, 2005.
14. Sengupta S, Amling C, D'Amico A and Blute ML: Prostate-specific antigen kinetics in the management of prostate cancer. J Urol 179: 821-826, 2008.
15. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP and Zattoni F: EAU Guidelines on Prostate Cancer. Eur Urol 53(1): 68-80, 2008.
16. PSA doubling-time calculator. URL: http://www.mskcc.org/mskcc/html/10088. cfm
17. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D and Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376-1383, 2003. (Pubitemid 37220457)
18. Patel A, Dorey F, Franklin J and de Kernion JB: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of PSA doubling times and log slope PSA. J Urol 158: 1441-1445, 1997.